Cipla Rises on Strong Q1 and U.S. Hopes

  Published 10 months ago

Cipla's profit beat estimates on strong India sales; U.S. launches expected to drive future growth amid mixed analyst views.

  • Cipla shares have gained 5% since results; 14 brokerages raised price targets, median now at Rs 1,723.5.
  • HSBC sees FY26 dip in gRevlimid sales but expects U.S. drug launches to cushion impact.
  • Goldman cautious on growth, Jefferies sees H2FY27 U.S. launches as key for future momentum.

You might like these

Navin Fluorine Q2 Profit Surges 152%

Zero GST Lifts Indian Irrigation Stocks

Eicher Motors Sales Surge in May 2025

HCLTech & The Standard Expand AI Partnership

IndiGo Expands Internationally, Challenges Air India

Nifty IT Falls 1% Amid Tariff Worries

V2 Retail Surpasses Growth Targets in Q1 FY26

News that matters the most ⚡